Overview

Dasatinib Holiday for Improved Tolerability

Status:
Active, not recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line) (DasaHIT Trial (Dasatinib Holiday for Improved Tolerability))

Phase:

Phase 3

Details

Lead Sponsor:

Prof. Dr. med. Andreas Hochhaus
University of Jena

Treatments:

Dasatinib